Peter Attia· MD
and even that CTP inhibitor that I mentioned that's still in development it's really more about reducing apob than it is about raising HDL
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
and even that CTP inhibitor that I mentioned that's still in development it's really more about reducing apob than it is about raising HDL
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
perhaps this CTP inhibitor could be part of the armamentarium to do that
there is still one CTP inhibitor obisattropin that is still in clinical development what differentiates it it's much more effective at lowering LDL and apob
it feels like the lp little a lowering is in conjunction with the LDL lowering but again sorry Peter I I'm I can't explain this I can't